Protean eGov Technologies Ltd (PROTEAN) is trading around ₹865 as of early November 2025, with the stock having a year high of ₹1,535 and a low near ₹716. The stock has declined roughly 35% over the last 6 months and about 42% year-on-year from its peak. Valuation metrics show a price-to-earnings (P/E) ratio near 37 and a price-to-book (P/B) ratio around 3.45, indicating a relatively high valuation considering recent price declines.
The company has zero debt, which strengthens its financial stability, but revenue growth has been weak with a recent contraction and modest sales increase in some quarters. Profitability margins remain moderate, and earnings per share (EPS) stood at around ₹23.3. Dividend yield is low at about 1.16%.
Technically, the stock is trading below its 200-day moving average (~₹1,053) and close to the 50-day average (~₹879), suggesting some near-term weakness. Support may be near the recent lows of ₹716, with resistance close to ₹900–₹950. Overall, Protean presents a cautious medium-term outlook, with fundamental strengths balanced by valuation and growth concerns.
The company has zero debt, which strengthens its financial stability, but revenue growth has been weak with a recent contraction and modest sales increase in some quarters. Profitability margins remain moderate, and earnings per share (EPS) stood at around ₹23.3. Dividend yield is low at about 1.16%.
Technically, the stock is trading below its 200-day moving average (~₹1,053) and close to the 50-day average (~₹879), suggesting some near-term weakness. Support may be near the recent lows of ₹716, with resistance close to ₹900–₹950. Overall, Protean presents a cautious medium-term outlook, with fundamental strengths balanced by valuation and growth concerns.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.